Holen Sie sich die Stockscreener-App
25.16
2.07%
0.51
Handel nachbörslich:
25.13
-0.03
-0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.65
Offen:
$24.745
24-Stunden-Volumen:
40.13M
Relative Volume:
0.96
Marktkapitalisierung:
$143.05B
Einnahmen:
$63.83B
Nettoeinkommen (Verlust:
$10.75B
KGV:
13.38
EPS:
1.88
Netto-Cashflow:
$12.44B
1W Leistung:
+5.14%
1M Leistung:
-1.91%
6M Leistung:
-1.87%
1J Leistung:
-12.79%
1-Tages-Spanne:
$24.74
$25.20
1-Wochen-Bereich:
$23.94
$25.20
52-Wochen-Spanne:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.16 | 139.75B | 63.83B | 10.75B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
660.49 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.42 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
201.47 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
121.20 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
82.71 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer Stock Is Making Moves On Promising Cancer Data. It Is Now A Buy? - Investor's Business Daily
Pfizer (PFE) Reports Promising Phase 3 Results For Bladder Cancer Treatment Combination - simplywall.st
Why is Pfizer Inc. stock going upMarket Movers & Weekly Breakout Stock Alerts - 선데이타임즈
Pfizer says FDA may pull its Covid vaccine for young children - Endpoints News
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer’s Promising Gene Therapy for Duchenne Muscular Dystrophy: A Key Market Player? - TipRanks
Pfizer’s Latest Study on HER2-positive Breast Cancer: Key Insights for Investors - TipRanks
Pfizer’s New Cancer Study: A Potential Game Changer? - TipRanks
FDA may pull authorization for Pfizer COVID shot for kids under 5 - The Hill
Pfizer’s Zavegepant Study: A New Hope for Migraine Relief in Asia - TipRanks
Should You Now Consider Selling Your Pfizer (PFE) Shares Before its Too Late? - Yahoo Finance
Cantor Fitzgerald maintains Neutral rating on Pfizer stock at $24 price target - Investing.com
FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age - Fox Business
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer - Yahoo Finance
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Pfizer Stock Surges on Revised Earnings Guidance as $850M Trading Volume Ranks 117th Amid Valuation Discount to Peers - AInvest
Pfizer/BioNTech may not win FDA renewal for pediatric COVID shot: report - MSN
Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study - insights.citeline.com
Pfizer (PFE) Reports Positive Phase 3 Results In Bladder Cancer Treatment Study - simplywall.st
Pfizer Raises Its Guidance And Analysts Up Their TargetsPFE Stock Looks Cheap - Barchart.com
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly - The Globe and Mail
Pfizer looks to expand ADC use after positive bladder cancer data - BioPharma Dive
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: Key Insights for Investors - TipRanks
Pfizer and Astellas Pharma’s Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer’s Abrocitinib Study: A Potential Game-Changer for Atopic Dermatitis Treatment - TipRanks
Pfizer’s MagnetisMM-4 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5 - Stocktwits
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE) - Benzinga
BlinkRx’s Ties to Donald Trump Jr. Questioned Amid Pfizer and Elicio Therapeutics’ Cancer Research Updates - geneonline.com
Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman - Yahoo Finance
Implications of Potential Pfizer Pediatric Vaccine Withdrawal on the U.S. Immunization Market - AInvest
Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail
Pfizer's combination therapy improves survival in bladder cancer trial - Reuters
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business - simplywall.st
Statutory Profit Doesn't Reflect How Good Pfizer's (NYSE:PFE) Earnings Are - Yahoo Finance
FDA Weighs Pulling Pfizer’s Covid Vaccine for Kids Under Age 5 - Bloomberg.com
Pfizer’s combination therapy improves survival in bladder cancer trial - PharmaLive
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer - Seeking Alpha
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - Yahoo Finance
Pfizer and Merck's Bladder Cancer Breakthrough: A Paradigm Shift in Oncology and a Win for Shareholders? - AInvest
Pfizer-Astellas bladder cancer therapy shows survival benefits in trial By Investing.com - Investing.com South Africa
Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment - TipRanks
Pfizer drug extends survival for some bladder cancer patients | STAT - statnews.com
Pfizer’s Padcev Plus Keytruda Extends Bladder Cancer Survival - Bloomberg.com
Eli Lilly, Pfizer Seek Spot in China Private Insurance Catalog - Bloomberg.com
Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock? - Yahoo Finance
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today - Yahoo Finance
Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors - Insider Monkey
Astrocytoma Market to See Strong Growth Through 2034 as Pfizer, - openPR.com
Pfizer workers taken to hospital for 'potential exposure to materials,' company says - WWMT
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):